Allele News and Research

RSS

Some African descent men may have higher genetic risk of developing prostate cancer

Some men of African descent may have a higher genetic risk of developing prostate cancer, according to research conducted at the Keck School of Medicine of the University of Southern California.

24 May 2011

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

Quintiles, the world's leading biopharmaceutical services company, and Population Genetics Technologies Ltd., creator of innovative solutions to reduce the costs and complexity of large-scale genomic testing and enable correlations with clinical outcomes, today announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.

17 May 2011

Researchers design new tool for identifying protein function from genetic code

Mayo Clinic researchers have designed a new tool for identifying protein function from genetic code. A team led by Stephen Ekker, Ph.D., succeeded in switching individual genes off and on in zebrafish, then observing embryonic and juvenile development.

10 May 2011

Scientists identify new risk gene variant for depression

Max Planck scientists uncover surprising genetic links. Scientists from the Max Planck Institute for Psychiatry in Munich have compared the genomes of a total of 4,088 patients and 11,001 healthy control subjects from all over the world and identified a new risk gene variant for depression.

28 Apr 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Roche launces new GS GType HLA Primer Sets for HLA genotyping

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci of the Human Leukocyte Antigen (HLA) genes.

30 Mar 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

Asuragen, Inc. announced that they have achieved CE-marking and commercial launch in Europe of the AmplideX FMR1 PCR Kit for the detection of CGG repeats in the fragile X mental retardation gene.

23 Mar 2011

New Neurotez method can predict genetic factors responsible for AD

The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject's risk for getting Alzheimer's disease, based on her/his TOMM40/APOE haplotype.

22 Mar 2011

Study identifies gene linked to higher risk of multiple sclerosis in children

Canadians have one of the highest rates of Multiple Sclerosis (MS) in the world with approximately 1,000 new cases diagnosed each year. Primarily striking in adulthood, physicians and researchers with the Canadian Pediatric Demyelinating Diseases Network (CPDDN), a multi-institutional and multidisciplinary group, have found that MS is being increasingly diagnosed in children.

21 Mar 2011

Genetic variant contributes to higher risk of lung cancer, increases tendency to smoke more

Norwegian researchers have discovered genes that increase not only one's risk of lung cancer, but perhaps one's urge to smoke as well. Now these researchers are working on developing a blood test for lung cancer.

11 Mar 2011

RainDance, 454 Life Sciences collaborate to launch core ADME gene screening research panel

RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today announced a collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for the simple and cost-effective investigation of drug absorption, distribution, metabolism, and excretion (ADME).

9 Mar 2011

Psychosocially hazardous neighborhood may influence cognitive function in older age

Residing in a psychosocially hazardous neighborhood is associated with worse cognitive function in older age for persons with the apolipoprotein E ε4 allele, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

9 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Allele News and Research

Some African descent men may have higher genetic risk of developing prostate cancer

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

Researchers design new tool for identifying protein function from genetic code

Scientists identify new risk gene variant for depression

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Life Technologies launches new TaqMan Mutation Detection Assays

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Roche launces new GS GType HLA Primer Sets for HLA genotyping

Transgenomic discovers novel BLOCker-Sequencing technology

Asuragen introduces CE-mark approved AmplideX FMR1 PCR Kit

New Neurotez method can predict genetic factors responsible for AD

Study identifies gene linked to higher risk of multiple sclerosis in children

Genetic variant contributes to higher risk of lung cancer, increases tendency to smoke more

RainDance, 454 Life Sciences collaborate to launch core ADME gene screening research panel

Psychosocially hazardous neighborhood may influence cognitive function in older age

Affymetrix releases complete genotyping data set on its website

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News